期刊文献+

LC-MS法测定血浆盐酸托烷司琼含量 被引量:1

Determination of tropisetron hydrochloride in plasma by liquid chromatograph-mass spectrometer
暂未订购
导出
摘要 目的盐酸托烷司琼片为Ⅳ类新药,为节约开发费用,更好的控制质量,建立了本品血浆含量检测方法。方法建立以LC-MS法测定盐酸托烷司琼血浆含量的方法,色谱柱为HypersilGoldC18柱(150×2.1mm,5μm);流动相为甲醇:水(用醋酸调整pH值为4.8)=52:48;流速为0.2mL·min-1,选用ESI离子源,采用正离子方式、目标二级离子选择反应离子扫描(SRM),扫描时间为0.03s,测定盐酸托烷司琼的含量。结果线性回收方程:Y=0.0131231+0.0328806X,采用1/X2加权,相关系数为0.9924,线性范围:0.2~40ng·mL-1。平均回收率98.55%,RSD<10%。结论此种方法准确、稳定,适用于盐酸托烷司琼的血浆含量测定。 Objective Tropisetron hydrochloride tablets is the fouth new drugs, in order to save de- velopment costs and better quality control, A method for determining tropisetron hydrochloride in plasma by liquid chromatograph-mass spectrometer was developed. Method LC-MS detection with positive model was described, granisetron hydrochloride was used as the intemal standard. After centrifuging, 5μL super- natant was injected into a Cls Shim-pack 150 mm × 2.1mm I.D. column. Mobile phase consisted of methanol and pure water (adjusted to pH 4.8) with a volume ratio of 52:48. The flow rate was of 0.2 mL.min-1. ESI ion source and selective reaction monitoring was used, and the scan time is 0.03s. Results The recovery of the method was more than 90%. The linear range was 0.2-40 ng·mL^-1 (r^2= 0.9924)with a minimum detectable limit of 0.2 ng·mL^-1. The stability analysis showed that plasma sample was stable in different conditions. The average recovery rate is 98.55%, and relative standard deviation is less than 10%. Conclusion The method had a good selectivity and reproducibility and can be used for the investigation of tropisetron hydrochloride in human plasma.
出处 《肿瘤药学》 CAS 2011年第3期223-226,234,共5页 Anti-Tumor Pharmacy
关键词 盐酸托烷司琼:LC-MS法 含量测定 Tropisetron Hydrochloride Liquid Chromatograph-mass Spectrometer, Plasma
  • 相关文献

参考文献4

二级参考文献16

  • 1刘宇,陆军,陈宁,苏国强.止吐药盐酸托烷司琼的合成[J].华西药学杂志,2004,19(6):433-434. 被引量:3
  • 2黄熠.紫外分光光度法测定盐酸托烷司琼片含量[J].安徽医药,2004,8(4):285-286. 被引量:4
  • 3徐红蓉,李雪宁,陈伟力.单剂口服盐酸托烷司琼颗粒剂在健康人体的生物等效性[J].中国临床药理学杂志,2005,21(3):194-197. 被引量:5
  • 4孙成婷.HPLC法测定盐酸托烷司琼的含量[J].中国药品标准,2007,8(3):64-66. 被引量:4
  • 5Fisher V, Baldeck JP, Francis LS. TSE. Pharmacokinetics and metablism of 5-hydroxytryptamine antagonidt tropisetron after single oral doses in humans[J]. Drug Metab Disps, 1992,20(4):603-6.
  • 6Hoyer D, Neijt HC, Wober C et al. Competitive interaction of agonists and antogists with 5-HT3 recogition site in membranes of neuroblastma cells labeled with [3H] ICS 205~930[J]. J Recept Res, 1989,9(1):65-9.
  • 7Hoyer D, Wober C, Neijt HC, Palacios JM. Palacios: 5-HT3 recognition sites in the central and peripheniral nervius system:Autoradiographic and radioligand binding studies[J]. Br J Pharmacol, 1989,96(suppl):7.
  • 8SIMPSON K,SPENCER C M,MCCLELLAN K J.Tropisetron-an upday of its use in the prevention of chemotherapy-induced nausea and vomiting[J].Drugs,2000,59(6):1297-1315.
  • 9KEES F,FARBER L,BUCHER M.Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers[J].J Clin Pharmacol,2001,52:705-707.
  • 10MICHELLE D,SUZANNE L,GILLES C.High-resolution liquid chromatographic method using ultraviolet detection for determination of ondansetron in human plasma[J].J Chromatogr,1997,693:399-406.

共引文献8

同被引文献16

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部